The warning affects all treatments containing GLP-1 receptor agonists, including semaglutide ( Ozempic, Wegovy, Rybelsus ), ...

The first GLP-1 medication was prescribed beginning in 2006, and the authors included cases beginning in 2000 to increase the power of the study, they noted. (NewMediaWire) - November 11, 2024 - ...

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 ...

Poor bowel preparation also led to repeat colonoscopies for 18.9% of current GLP-1RA users, compared to 11.1% of controls ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new recommendations.

Low-income patients' access to blockbuster weight-loss drugs through Medicaid remains limited, a new KFF analysis has found.

Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011 ...

GLP-1: Glucagon-like peptide-1; RA: receptor agonist. ACS: Acute coronary syndrome ... result in significant decrease in efficacy of the medication class. LA GLP1-RAs in studies to date appear ...

"This case report highlights a rare phenomenon linked to individual variations in response to GLP-1 receptor agonist treatment. In clinical practice, it is crucial to quickly recognize such ...

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the ... while newer GLP-1-targeting drugs like Ozempic and Wegovy, as well as Eli Lilly’s ...